Results 191 to 200 of about 7,834 (208)

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer

Journal of Clinical Pharmacology, 2020
Yanke Yu, Chandrasekar Durairaj
exaly  

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

New England Journal of Medicine, 2018
Jennifer K Litton, Hope S Rugo, Sara A Hurvitz   +2 more
exaly  

UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis, 2020
Lei Ye, Jingjing Chen, Shuang-Long Li
exaly  

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European Journal of Cancer, 2018
Sara A Hurvitz, Judith Balmana, Mark E Robson   +2 more
exaly  

Talazoparib and Thoracic RT for ES-SCLC

Case Medical Research, 2019
openaire   +1 more source

Talazoparib for BRCA-mutated advanced breast cancer

The Lancet Oncology, 2018
openaire   +1 more source

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of Oncology, 2018
Miguel Martin
exaly  

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review

Cancer Chemotherapy and Pharmacology
Saphal Lakshmi, Pasupulati, Katiboina, Srinivasa Rao, Sushil, Sharma, C, Madhavrao, Gaurav, Rangari, Arup Kumar, Misra, L V Simhachalam, Kutikuppala, T, Devika, Sandhya Rani, Sarikonda   +8 more
openaire   +2 more sources

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

Drug Resistance Updates
Shuo Fang
exaly  

Aciclovir/Gemtuzumab-ozogamicin/Talazoparib

Reactions Weekly
openaire   +1 more source